Voyager Therapeutics, Inc. Stock price

Equities

VYGR

US92915B1061

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
9.09 USD -2.05% Intraday chart for Voyager Therapeutics, Inc. +0.33% +7.70%
Sales 2024 * 36.62M Sales 2025 * 46.8M Capitalization 494M
Net income 2024 * -101M Net income 2025 * -112M EV / Sales 2024 * 4.84 x
Net cash position 2024 * 316M Net cash position 2025 * 373M EV / Sales 2025 * 2.57 x
P/E ratio 2024 *
-4.89 x
P/E ratio 2025 *
-4.81 x
Employees 162
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.69%
More Fundamentals * Assessed data
Dynamic Chart
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) added to S&P Biotechnology Select Industry Index CI
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer MT
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 CI
Citigroup Starts Voyager Therapeutics With Buy Rating, $16 Price Target MT
Transcript : Voyager Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Voyager Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment CI
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research CI
Certain Restricted Stock Units of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024. CI
Certain Stock Options of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024. CI
Certain Common Stock of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024. CI
Transcript : Voyager Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM
Wedbush Trims Voyager Therapeutics' Price Target to $10 From $11, Neutral Rating Kept MT
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health... Our Logo
More news
1 day-2.05%
1 week-2.99%
Current month+9.25%
1 month+20.40%
3 months+13.91%
6 months+14.20%
Current year+7.70%
More quotes
1 week
8.84
Extreme 8.84
9.41
1 month
7.33
Extreme 7.33
10.63
Current year
7.01
Extreme 7.01
11.72
1 year
6.06
Extreme 6.06
14.34
3 years
2.46
Extreme 2.46
14.34
5 years
2.46
Extreme 2.46
28.79
10 years
2.46
Extreme 2.46
31.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 22-02-28
Chairman 61 15-07-21
Director of Finance/CFO 55 22-09-18
Members of the board TitleAgeSince
Director/Board Member 75 23-05-08
Director/Board Member 70 13-12-31
Director/Board Member 68 17-01-04
More insiders
Date Price Change Volume
24-03-18 9.09 -2.05% 764,131
24-03-15 9.28 +1.64% 3,891,945
24-03-14 9.13 -0.11% 461,668
24-03-13 9.14 +0.55% 535,334
24-03-12 9.09 +0.33% 669,381

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Voyager Therapeutics, Inc. is a biotechnology company. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines. Its gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. It has developed an AAV capsid discovery platform called Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACERTM) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (BBB). Its pipeline programs include superoxide dismutase 1 (SOD1), gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer's disease.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.09 USD
Average target price
15.43 USD
Spread / Average Target
+69.73%
Consensus
  1. Stock
  2. Equities
  3. Stock Voyager Therapeutics, Inc. - Nasdaq